Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - methylphenidate hydrochloride, quantity: 10 mg - tablet, uncoated - excipient ingredients: calcium phosphate; magnesium stearate; gelatin; purified talc; wheat starch; lactose monohydrate - ritalin 10 tablets and ritalin la capsules are indicated for the treatment of adhd. ritalin 10 tablets are also indicated for the treatment of narcolepsy. attention-deficit hyperactivity disorder (adhd) adhd was previously known as attention-deficit disorder. other terms used to describe this behavioural syndrome include: minimal brain dysfunction in children, hyperkinetic child syndrome, minimal brain damage, minimal cerebral dysfunction, minor cerebral dysfunction and psycho-organic syndrome of children. ritalin 10 / ritalin la are indicatedas an integral part of a total treatment program for adhd that may include other measures (psychological, educational and social) for patients with this syndrome. stimulants are not intended for use in the patient who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. special diagnostic considerations for adhd in children: the aetiology of this syndrome is unknown and there is no single diagnostic test.

Singapore - English - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - methylphenidate hcl - tablet, film coated - 20 mg - methylphenidate hcl 20 mg

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - methylphenidate hydrochloride 10mg;   - tablet - 10 mg - active: methylphenidate hydrochloride 10mg   excipient: calcium phosphate gelatin lactose monohydrate magnesium stearate purified talc wheat starch - ritalin/ritalin sr is indicated in the treatment of attention-deficit/hyperactivity disorder in children aged 6 years or older. ritalin la is indicated in the treatment of attention-deficit/hyperactivity disorder in children aged 6 years or older and in adults. ritalin/ritalin sr is indicated for the treatment of narcolepsy in adults. symptoms include daytime sleepiness, inappropriate sleep episodes, and sudden loss of voluntary muscle tone.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - methylphenidate hydrochloride 20mg;  ;   - modified release tablet - 20 mg - active: methylphenidate hydrochloride 20mg     excipient: carbon dioxide carnauba wax cetostearyl alcohol hypromellose ink lactose monohydrate magnesium stearate methylated spirits polyethylene glycol hydrogenated castor oil purified talc purified water titanium dioxide - ritalin/ritalin sr is indicated in the treatment of attention-deficit/hyperactivity disorder in children aged 6 years or older. ritalin la is indicated in the treatment of attention-deficit/hyperactivity disorder in children aged 6 years or older and in adults. ritalin/ritalin sr is indicated for the treatment of narcolepsy in adults. symptoms include daytime sleepiness, inappropriate sleep episodes, and sudden loss of voluntary muscle tone.

Israel - English - Ministry of Health

novartis israel ltd - methylphenidate hydrochloride - tablets - methylphenidate hydrochloride 20 mg - methylphenidate - attention deficit hyperactivity disorders . narcolepsy.

Israel - English - Ministry of Health

novartis israel ltd - methylphenidate hydrochloride - tablets - methylphenidate hydrochloride 10 mg - methylphenidate - methylphenidate - attention deficit hyperactivity disorder (adhd). narcolepsy.

Singapore - English - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - methylphenidate hcl - tablet - 10 mg - methylphenidate hcl 10 mg

Canada - English - Health Canada

novartis pharmaceuticals canada inc - methylphenidate hydrochloride - tablet (extended-release) - 20mg - methylphenidate hydrochloride 20mg - respiratory and cns stimulants

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - methylphenidate hydrochloride (unii: 4b3sc438hi) (methylphenidate - unii:207zz9qz49) - methylphenidate hydrochloride 5 mg - attention deficit disorders (previously known as minimal brain dysfunction in children). other terms being used to describe the behavioral syndrome below include: hyperkinetic child syndrome, minimal brain damage, minimal cerebral dysfunction, minor cerebral dysfunction. ritalin is indicated as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. the diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. nonlocalizing (soft) neurological signs, learning disability, and abnormal eeg may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted. specific etiology of this

Israel - English - Ministry of Health

teva pharmaceutical industries ltd, israel - dipyrone - tablets - dipyrone 500 mg - metamizole sodium - metamizole sodium - relief of moderate to severe pain as in headache, toothache, dysmenorrhea andfor high fever that does not respond to other measures.